Key result
Diabetes linked to ~55% higher clopidogrel resistance risk, while male sex and smoking lower odds.
Why the study?
Clopidogrel resistance is prevalent after ischemic stroke or TIA and leads to recurrent events, but reported associations for its risk factors remain inconsistent.
What are the sociodemographic, clinical, and genetic predictors of clopidogrel resistance in patients with ischemic stroke or TIA?
Comparison
Clopidogrel-resistant vs non-resistant patients
Design
Systematic review and meta-analysis
Authors
Loading...
Encourages caution with clopidogrel in diabetic patients; leaves open optimal antiplatelet regimens pending randomized trial confirmation.
Meta-Analysis (n=11,786)
What are the sociodemographic, clinical, and genetic predictors of clopidogrel resistance in patients with ischemic stroke or TIA?
Effect estimate: OR 1.55 (95% CI 1.22-1.97)
Clopidogrel resistance in stroke/TIA patients is multifactorial, driven by older age, diabetes, poor glycemic control, female sex, non-smoking status, and genetic factors.
Omar et al. (2026) conducted a meta-analysis in Ischemic stroke or TIA (n=11,786). Risk factors for clopidogrel resistance vs. Non-resistant patients was evaluated on clopidogrel resistance (OR 1.55, 95% CI 1.22-1.97). Diabetes mellitus increased the odds of clopidogrel resistance (OR 1.55; 95% CI 1.22–1.97), whereas male sex, current smoking, and the CYP2C19 2 GG genotype (OR 0.45; 95% CI 0.26–0.78) lowered odds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: